Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.43 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 3/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | CASP3 | P42574 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3016756 | 1.00 | CHRNB2 (0.43) | CHRNB2CHRNA4AKT1KDM4EPOLB | |
| SCHEMBL3018045 | 0.83 | EGFR (0.41) | CHRNB2CHRNA4KDM4EMAPTHTT | |
| SCHEMBL3018038 | 0.83 | EGFR (0.41) | CHRNB2CHRNA4KDM4EMAPTHTT | |
| SCHEMBL2441523 | 0.81 | CHRNB2 (0.64) | CHRNB2CHRNA4AKT1KDM4ECHRNB4 | |
| SCHEMBL2441525 | 0.81 | CHRNB2 (0.64) | CHRNB2CHRNA4AKT1KDM4ECHRNB4 | |
| SCHEMBL6453851 | 0.78 | CHRNB2 (0.38) | CHRNB2CHRNA4AKT1KDM4EPOLB | |
| SCHEMBL6453858 | 0.78 | CHRNB2 (0.38) | CHRNB2CHRNA4AKT1KDM4EPOLB | |
| SCHEMBL3017873 | 0.78 | CHRNB2 (0.53) | CHRNB2CHRNA4AKT1CHRNB4CHRNA3 | |
| SCHEMBL3017868 | 0.78 | CHRNB2 (0.53) | CHRNB2CHRNA4AKT1CHRNB4CHRNA3 | |
| SCHEMBL7293349 | 0.78 | ALDH1A1 (0.40) | CHRNB2CHRNA4AKT1KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288420-B2 | Compounds capable of activating cholinergic receptors | TARGACEPT, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| EP-2253616-A1 | Process for the preparation of compounds capable of activating cholinergic receptors | Targacept, Inc. (US) | 2010-11-24 | — | — | EP | disclosed |
| US-7790757-B2 | Compounds capable of activating cholinergic receptors | TARGACEPT, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20100222395-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2010-09-02 | — | — | US | disclosed |
| US-20100204481-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2010-08-12 | — | — | US | disclosed |
| US-20100160390-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100121061-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20080214628-A1 | Compounds Capable of Activating Cholinergic Receptors | CALDWELL WILLIAM SCOTT | 2008-09-04 | — | — | US | disclosed |
| US-20080139809-A1 | Compounds Capable of Activating Cholinergic Receptors | CALDWELL WILLIAM SCOTT | 2008-06-12 | — | — | US | disclosed |
| US-7307092-B2 | Compounds Capable of Activating Cholinergic Receptors | TARGACEPT, INC. (US) | 2007-12-11 | — | — | US | disclosed |
| EP-1086082-B1 | ARYLSUBSTITUTED OLEFINIC AMINES AND THEIR USE AS CHOLINERGIC RECEPTORS AGONISTS | TARGACEPT INC (US) | 2004-08-18 | — | — | EP | disclosed |
| WO-2004031151-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2004-04-15 | — | — | WO | disclosed |
| US-20030125345-A1 | Nicotinic compounds; treating central nervous system disorders | TARGACEPT, INC. | 2003-07-03 | — | — | US | disclosed |
| US-20030087915-A1 | Pharmaceutical compositions and methods for use | DULL GARY MAURICE (US) | 2003-05-08 | — | — | US | disclosed |
| US-6492399-B1 | SUCH AS N-METHYL-4-(3-(5-NITRO-6-AMINOPYRIDIN)YL)-3-BUTEN-1-AMINE; NICOTINIC CHOLINERGIC RECEPTOR AGONISTS | TARGACEPT, INC. | 2002-12-10 | — | — | US | disclosed |
| US-6455554-B1 | COMPOUNDS CAPABLE OF AFFECTING NICOTINIC CHOLINERGIC RECEPTORS; TREATOMG CENTRAL NERVOUS SYSTEM DISORDERS | TARGACEPT, INC. | 2002-09-24 | — | — | US | disclosed |
| US-20020052497-A1 | Compounds capable of activating cholinergic receptors | TARGACEPT, INC. | 2002-05-02 | — | — | US | disclosed |
| EP-1185514-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | Targacept, Inc. (US) | 2002-03-13 | — | — | EP | disclosed |
| US-6232316-B1 | SUCH AS PARKINSON'S DISEASE, TOURETTE'S SYNDROME, SCHIZOPHRENIA, AND SENILE DEMENTIA OF ALZHEIMERS DISEASE | TARGACEPT, INC. | 2001-05-15 | — | — | US | disclosed |
| WO-2000075110-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TARGACEPT, INC. (US) | 2000-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052497-A1 | Compounds capable of activating cholinergic receptors | CHRNA4, CHRNB4, CHRM4 | CHRNB2 4/4885CHRNA4 1/4885AKT1 2634/4885 |
| US-20100222395-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | CHRNA4, CHRNB4, CHRM4 | CHRNB2 4/4885CHRNA4 1/4885AKT1 2634/4885 |
| US-20100204481-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | CHRNA4, CHRNB4, CHRM4 | CHRNB2 4/4885CHRNA4 1/4885AKT1 2634/4885 |
| US-20030125345-A1 | Nicotinic compounds; treating central nervous system disorders | SLC6A2, CHRNA6, CHRNA10 | CHRNB2 9/4885CHRNA4 7/4885AKT1 2394/4885 |
| US-20080139809-A1 | Compounds Capable of Activating Cholinergic Receptors | CHRNA4, CHRNB4, CHRM4 | CHRNB2 4/4885CHRNA4 1/4885AKT1 2634/4885 |
| US-20030087915-A1 | Pharmaceutical compositions and methods for use | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP4B1, HTR3E | CHRNB2 227/4885CHRNA4 145/4885AKT1 3878/4885 |
| US-20080214628-A1 | Compounds Capable of Activating Cholinergic Receptors | CHRNA4, CHRNB4, CHRM4 | CHRNB2 4/4885CHRNA4 1/4885AKT1 2634/4885 |
| US-20100121061-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | CHRM3, CHRM5, CHRM4 | CHRNB2 14/4885CHRNA4 9/4885AKT1 1789/4885 |
| US-20100160390-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | CHRNA4, CHRNB4, CHRM4 | CHRNB2 4/4885CHRNA4 1/4885AKT1 2634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.